CN114392260A - Medicine for relieving anxiety and depression - Google Patents
Medicine for relieving anxiety and depression Download PDFInfo
- Publication number
- CN114392260A CN114392260A CN202210135820.6A CN202210135820A CN114392260A CN 114392260 A CN114392260 A CN 114392260A CN 202210135820 A CN202210135820 A CN 202210135820A CN 114392260 A CN114392260 A CN 114392260A
- Authority
- CN
- China
- Prior art keywords
- extract
- acid
- chloroform
- ethyl acetate
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000019901 Anxiety disease Diseases 0.000 title claims abstract description 19
- 230000036506 anxiety Effects 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 229940079593 drug Drugs 0.000 title claims description 5
- 239000000284 extract Substances 0.000 claims abstract description 38
- 241000195954 Lycopodium clavatum Species 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 30
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 238000000605 extraction Methods 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000012530 fluid Substances 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 9
- JLIDBLDQVAYHNE-YKALOCIXSA-N (+)-Abscisic acid Chemical compound OC(=O)/C=C(/C)\C=C\[C@@]1(O)C(C)=CC(=O)CC1(C)C JLIDBLDQVAYHNE-YKALOCIXSA-N 0.000 claims description 8
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 7
- BCZFSDNVXODRAJ-JTTNIQEDSA-N lycopodine Chemical compound C1CCN2CCC[C@@H]3[C@H]4C[C@@H](C)C[C@]32[C@H]1C(=O)C4 BCZFSDNVXODRAJ-JTTNIQEDSA-N 0.000 claims description 7
- BCZFSDNVXODRAJ-ZHMBSYLPSA-N lycopodine Natural products C1CCN2CCC[C@@H]3[C@H]4C[C@H](C)C[C@]32[C@H]1C(=O)C4 BCZFSDNVXODRAJ-ZHMBSYLPSA-N 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 239000011975 tartaric acid Substances 0.000 claims description 7
- 235000002906 tartaric acid Nutrition 0.000 claims description 7
- WDKYDMULARNCIS-GQCTYLIASA-N Caffeic acid ethyl ester Chemical compound CCOC(=O)\C=C\C1=CC=C(O)C(O)=C1 WDKYDMULARNCIS-GQCTYLIASA-N 0.000 claims description 6
- 241000196324 Embryophyta Species 0.000 claims description 6
- 150000001204 N-oxides Chemical class 0.000 claims description 6
- 239000002026 chloroform extract Substances 0.000 claims description 6
- 239000002024 ethyl acetate extract Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- JJPMUZRSJKMFRK-OQMKEHIESA-N Lycodine Chemical class N1CCC[C@@H]2[C@H]3C[C@@H](C)C[C@]21C1=CC=CN=C1C3 JJPMUZRSJKMFRK-OQMKEHIESA-N 0.000 claims description 5
- UQSRXQMIXSZGLA-UHFFFAOYSA-N 2,4-dihydroxy-6-methylbenzoic acid ethyl ester Chemical compound CCOC(=O)C1=C(C)C=C(O)C=C1O UQSRXQMIXSZGLA-UHFFFAOYSA-N 0.000 claims description 4
- 235000008582 Pinus sylvestris Nutrition 0.000 claims description 4
- FCRACOPGPMPSHN-UHFFFAOYSA-N desoxyabscisic acid Natural products OC(=O)C=C(C)C=CC1C(C)=CC(=O)CC1(C)C FCRACOPGPMPSHN-UHFFFAOYSA-N 0.000 claims description 4
- WDKYDMULARNCIS-UHFFFAOYSA-N ethyl caffeoate Natural products CCOC(=O)C=CC1=CC=C(O)C(O)=C1 WDKYDMULARNCIS-UHFFFAOYSA-N 0.000 claims description 4
- NKHAVTQWNUWKEO-UHFFFAOYSA-N fumaric acid monomethyl ester Natural products COC(=O)C=CC(O)=O NKHAVTQWNUWKEO-UHFFFAOYSA-N 0.000 claims description 4
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 claims description 4
- NKHAVTQWNUWKEO-NSCUHMNNSA-N monomethyl fumarate Chemical compound COC(=O)\C=C\C(O)=O NKHAVTQWNUWKEO-NSCUHMNNSA-N 0.000 claims description 4
- 229940005650 monomethyl fumarate Drugs 0.000 claims description 4
- 239000001839 pinus sylvestris Substances 0.000 claims description 4
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 claims description 4
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- JJPMUZRSJKMFRK-JXFSHQFZSA-N lycodine Natural products N1CCC[C@@H]2[C@@H]3C[C@@H](C)C[C@@]21C1=CC=CN=C1C3 JJPMUZRSJKMFRK-JXFSHQFZSA-N 0.000 claims description 3
- XUQXZROVMZNKPO-UHFFFAOYSA-N 3-(4-Hydroxy-3-methoxyphenyl)-2-methylpropionic acid Chemical compound COC1=CC(CC(C)C(O)=O)=CC=C1O XUQXZROVMZNKPO-UHFFFAOYSA-N 0.000 claims description 2
- WWKZTBLUGXLBSQ-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1.COC1=CC=C(C(O)=O)C=C1 WWKZTBLUGXLBSQ-UHFFFAOYSA-N 0.000 claims description 2
- SJIMDGIDDDGXLI-UHFFFAOYSA-N Lycoflexin Natural products C1C(=O)C2(C3)CCCN3CCCC32C1CC(C)CC3=O SJIMDGIDDDGXLI-UHFFFAOYSA-N 0.000 claims description 2
- SJIMDGIDDDGXLI-OSRSDYAFSA-N Lycoflexine Chemical compound C([C@]1(C2)C(=O)C3)CCN2CCC[C@@]21[C@H]3C[C@@H](C)CC2=O SJIMDGIDDDGXLI-OSRSDYAFSA-N 0.000 claims description 2
- CTKJRXIVYBGZEW-QXMHVHEDSA-N ethyl (z)-tetracos-15-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(=O)OCC CTKJRXIVYBGZEW-QXMHVHEDSA-N 0.000 claims description 2
- XFJQZDADXNOFTQ-UHFFFAOYSA-N ethyl 3-(4-hydroxy-3-methoxyphenyl)propanoate Chemical compound CCOC(=O)CCC1=CC=C(O)C(OC)=C1 XFJQZDADXNOFTQ-UHFFFAOYSA-N 0.000 claims description 2
- -1 ethyl dihydroferulic acid Chemical compound 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- SJIMDGIDDDGXLI-KFZJALRRSA-N lycoflexine Natural products C[C@@H]1C[C@@H]2CC(=O)[C@]34CCCN(CCC[C@@]23C(=O)C1)C4 SJIMDGIDDDGXLI-KFZJALRRSA-N 0.000 claims description 2
- PDTCYIZPTRRYOT-UHFFFAOYSA-N methyl 3-(4-hydroxy-3-methoxyphenyl)propanoate Chemical compound COC(=O)CCC1=CC=C(O)C(OC)=C1 PDTCYIZPTRRYOT-UHFFFAOYSA-N 0.000 claims description 2
- 229940050176 methyl chloride Drugs 0.000 claims description 2
- NCUJRUDLFCGVOE-UHFFFAOYSA-N noreugenin Chemical compound C1=C(O)C=C2OC(C)=CC(=O)C2=C1O NCUJRUDLFCGVOE-UHFFFAOYSA-N 0.000 claims description 2
- AZTPTPPLNRTTGQ-UHFFFAOYSA-N noreugenin Natural products OC1=CC(O)=C2C(=O)C(C)=COC2=C1 AZTPTPPLNRTTGQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000008346 aqueous phase Substances 0.000 claims 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 241000218626 Pinus sylvestris Species 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- 240000005020 Acaciella glauca Species 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- AHOUBRCZNHFOSL-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine Chemical compound C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
- 102000012440 Acetylcholinesterase Human genes 0.000 description 2
- 108010022752 Acetylcholinesterase Proteins 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 229940022698 acetylcholinesterase Drugs 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
- 229960004801 imipramine Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 238000004237 preparative chromatography Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 240000000559 Albizia odoratissima Species 0.000 description 1
- 235000011438 Albizia odoratissima Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000037740 Coptis chinensis Species 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000195948 Lycopodiaceae Species 0.000 description 1
- 241001124817 Lycopodiastrum Species 0.000 description 1
- 241000195947 Lycopodium Species 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229960002419 flupentixol Drugs 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960004794 melitracen Drugs 0.000 description 1
- GWWLWDURRGNSRS-UHFFFAOYSA-N melitracen Chemical compound C1=CC=C2C(=CCCN(C)C)C3=CC=CC=C3C(C)(C)C2=C1 GWWLWDURRGNSRS-UHFFFAOYSA-N 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960005183 paroxetine hydrochloride Drugs 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- 125000001474 phenylpropanoid group Chemical group 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Abstract
The invention discloses application of a lycopodium clavatum extract in preparing a medicament for relieving anxiety and depression and a preparation method thereof.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicine extracts, and relates to a traditional Chinese medicine extract for relieving anxiety and depression.
Background
Depression and anxiety disorder are common mental disorder psychological diseases, have the characteristics of high morbidity, high disability rate and high recurrence rate, and seriously affect human health, and the current clinical common antidepressant mainly takes western medicines such as imipramine, flupentixol melitracen tablets, novel antidepressant anxiety drug paroxetine hydrochloride and the like, but has the problems of more contraindications, large addiction, obvious side effect, easy recurrence after drug withdrawal, lower effective rate, poorer patient compliance and the like.
Depression and anxiety disorder belong to the category of depression in traditional Chinese medicine, and are mostly caused by qi stagnation, qi and blood dysfunction of viscera and imbalance of yin and yang due to emotional failure. In the treatment and rehabilitation and nursing processes of anxiety and depression, the traditional Chinese medicine has the advantages of multiple targets, multiple ways, multiple levels and multiple mechanisms. In recent years, various traditional Chinese medicines such as liquorice, albizia flower, fructus psoraleae, radix puerariae, coptis chinensis and the like are reported to have the effects of relieving anxiety and depression, the effective components comprise flavonoids, terpenes, phenylpropanoids, quinones, alkaloids and the like, and the effects are shown in various aspects such as the regulation of monoamine neurotransmitter biochemical abnormality, the regulation of the internal environment of an organism, the energy metabolism function and the like.
Caulis et folium Pothi Repentis (Lycopodiastrum casuarinioides (Spring) Holub ex Dixi) is a fern of Lycopodiaceae, and is also called "Shujincao" for relieving rigidity of muscles and promoting blood circulation, and can be used for treating rheumatic arthralgia, traumatic injury, arthralgia and myalgia, menoxenia and foot spasm. Mainly contains Lycodine type lycopine alkaloid, can resist bacteria, tumors, oxidation, blood sugar and inflammation, and has good acetylcholinesterase resisting activity. At present, no report is found on the effect of the traditional Chinese medicine for relieving anxiety and depression.
The invention further discovers that the lycopodium clavatum extract has the functions of relieving anxiety and depression, so the invention further discovers the potential of the lycopodium clavatum extract on treating new indications.
Disclosure of Invention
The invention aims to provide a medicine for relieving anxiety and depression, which mainly comprises the active ingredient of the whole plant extract of the lycopodium clavatum, and the specific technical scheme is as follows: a medicine for relieving anxiety and depression comprises an ethanol and/or methanol extract of Pinus sylvestris which is rich in alkaloid, has nerve cell protection function and acetylcholinesterase resisting activity, and can relieve anxiety and depression.
According to some embodiments of the invention, the method of preparing the lycopodium giganteum extract comprises the steps of: cleaning whole plant of herba Lycopodii Serrati, sun drying, weighing, pulverizing, extracting, filtering, drying to obtain extract, selecting ethanol and/or methanol as extraction solvent, collecting extractive solution, filtering, concentrating to obtain whole extract, extracting with different solvents, concentrating to obtain extract, and drying.
Detailed Description
In order to explain the technical content, the objects and the effects of the present invention in detail, the following description will be given with reference to the embodiments.
The test methods used in the examples are all conventional methods unless otherwise specified; the materials, reagents and the like used are commercially available reagents and materials unless otherwise specified.
Example 1:
a preparation method of a medicine for relieving anxiety and depression comprises pulverizing dried whole plant of radix et rhizoma Boussingaultiae Pseudochinensis 20kg, extracting with ethanol under reflux, filtering, and concentrating to obtain extract.
Further, adding tartaric acid aqueous solution and ethyl acetate into the extract for extraction, adjusting the pH value of a water phase, extracting with chloroform, and concentrating the extract to obtain the extract.
The method comprises the following specific steps: collecting dried herba Lycopodii Serrati 20kg, pulverizing, reflux extracting with 120L 70-90% ethanol for 3 times, each time for 2 hr, at 70-85 deg.C, and concentrating the extractive solution to obtain fluid extract 1.8 kg. Adding 3% tartaric acid water solution and ethyl acetate into the fluid extract, suspending to 20L, adding saturated Na into the water phase2CO3After adjusting the pH to 10, chloroform extraction was further performed to obtain an ethyl acetate extract (238 g) and a chloroform extract (60 g). And determining the main extraction components by silica gel column chromatography, polyamide column chromatography, HPLC semi-preparative chromatography and other separation means at the later stage.
An 80% ethanol solution is preferred as the extraction solvent.
Example 2:
a preparation method of a medicine for relieving anxiety and depression comprises collecting dried whole plant of radix et rhizoma Boussingaultiae Pseudobaselloidis 20kg, pulverizing, adding methanol, extracting under hot reflux, filtering, and concentrating to obtain extract.
Further, adding tartaric acid aqueous solution and ethyl acetate into the extract for extraction, adjusting the pH value of a water phase, extracting with chloroform, and concentrating the extract to obtain the extract.
The method comprises the following specific steps: collecting 20kg of dried whole plant of Pinus sylvestris, extracting with 120L 70-85% methanol under reflux for 3 times, each time for 2 hr, at 70-85 deg.C, and concentrating the extractive solution to obtain 2kg of total fluid extract. Adding 3% tartaric acid water solution and ethyl acetate into the fluid extract, suspending to 25L, adding saturated Na into the water phase2CO3After adjusting the pH to 10, chloroform extraction was further performed to obtain an ethyl acetate extract (256 g) and a chloroform extract (70 g). And determining the main extraction components by silica gel column chromatography, polyamide column chromatography, HPLC semi-preparative chromatography and other separation means at the later stage.
A75% methanol solution is preferred as the extraction solvent.
In order to make the technical means, technical features, objectives and effects achieved by the present invention easily understandable, the following experiments or experimental studies are used to further illustrate the present invention.
Experimental animals and groups
50 healthy Kunming mice with the weight of 20-25g and male sex are selected. After being fed for 1 week in a conventional adaptive manner, the animals were randomly divided into a model group, a positive control group (imipramine, dosage 20.0 mg/kg), a total fluid extract (A) group (dosage 200 mg/kg), an ethyl acetate (B) group (dosage 200 mg/kg) and a chloroform (C) group (dosage 200 mg/kg) according to body weight.
Tail suspension experiment
The 2cm part of the tail end of the mouse is attached to a horizontal stick, so that the animal is in an inverted hanging state, the head of the mouse is about 8cm away from the table surface, no place for the mouse to climb is arranged around the table surface, the two sides of the suspension are separated from the sight of the animal by baffles so as to prevent mutual interference, and the floating and motionless time of each animal within 6min after 4min is recorded. The tail-suspended mouse struggles to move for overcoming abnormal body positions, but after moving for a certain time, the tail-suspended mouse appears discontinuous immobility, and displays an 'despair' state.
Forced swimming experiment
Each group of mice is continuously administrated for 14 days, and after the last administration for 1h, each group of mice is independently put into a water tank (40 cm in height and 18cm in diameter) with the water depth of 15cm, the water temperature is 25 +/-1 ℃, the mice are adapted for 2min, then are forcedly swim for 6min, and the floating and motionless time of each mouse is observed and recorded within 6min and 4min later.
Results of the experiment
TABLE 1 Effect of the herbal extracts of the present invention on the time to keep the mice afloat and still for forced swimming
As a result: compared with the model group, the full-fluid extract A group, the ethyl acetate B group and the chloroform C group obviously shorten the time for keeping the tail suspended to float and the time for keeping the tail suspended to float in forced swimming, wherein the chloroform C group has the most obvious effect.
And (4) conclusion: the extract of Pinus sylvestris can effectively relieve anxiety and depression.
After later-stage identification:
ethyl acetate layer extraction ingredients: furfural (furfurfuraldehyde), monomethyl fumarate (monomethylfumarate), methyl dihydroferulic acid (dihydroferulic acid methyl ester), ethyl dihydroferulic acid (dihydroferulic acid ethyl ester), ethyl caffeate (caffeic acid ethyl ester), 5, 7-dihydroxy-2-methylchromone (5, 7-dihydroxy-2-methyl chloride), abscisic acid (abscisic acid), ethyl nervonate (ethyl orsellinate), 4-methoxybenzoic acid (4-methoxybenzoic acid), vanillic acid (vanillic acid).
Chloroform layer extraction of components: lycoserramine-M N-oxide, acetyl-lycoserramine-M, lycopodine (lycopodine), lycoserramine-M, miyoshinine C, 12-epoxydoline N-oxide, gnidiiodine, lycoserramine-K, lucidiline (lucidiline), 4 alpha-hydroxyyanhydroxodiol, flubelline; hydroxypyrodine, lycopodine (lycodine), des-N-methyl-alpha-phellodendrine (des-N-methyl-alpha-obstrurine), alpha-phellodendrine (alpha-obstrurine), des-N-methyl-beta-phellodendrine (des-N-methyl-beta-obstrurine), lycopodrine (lycoflexine), lycoflexidine N-oxide, fabridine (facettidine), N-oxideopine M.
The foregoing describes preferred embodiments of the present invention, but is not intended to limit the invention thereto. Modifications and variations of the embodiments disclosed herein may be made by those skilled in the art without departing from the scope and spirit of the invention.
Claims (10)
- The application of the Lycodine alkaloid in preparing the medicines for relieving anxiety and depression has the following main mother ring structure:
and
R1= OH、OCH3、HR2=CH3、HR3= H、CH2OH、OH。 - 2. an application of the extract of the lycopodine in preparing the medicines for relieving anxiety and depression, wherein the main effective component of the extract is the Lycodine alkaloid in the claim 1.
- 3. The use of claim 1, wherein the extract solvent is methanol and/or ethanol, and the extract is obtained by extracting with ethyl acetate, tartaric acid water, and chloroform.
- 4. The use of claim 3, wherein the extract is an ethyl acetate extract.
- 5. The use of claim 3, wherein the extract is a chloroform extract.
- 6. The method for preparing the extract as claimed in any one of claims 2 to 5, wherein the extraction solvent is ethanol, dried whole plant of Pinus sylvestris 20kg is taken, pulverized, extracted with 120L 70-90% ethanol under reflux for 3 times at 70-85 deg.C for 2h each time, the extract is concentrated to 1.8kg of total fluid extract, the fluid extract is added with 3% tartaric acid aqueous solution and ethyl acetate and suspended to 20L, and the lower aqueous phase is saturated Na2CO3After adjusting the pH to 10, chloroform was added thereto to extract, thereby obtaining an ethyl acetate extract and a chloroform extract.
- 7. The method for preparing the extract as claimed in any one of claims 2-5, wherein the extraction solvent is methanol, dried whole plant of Lycopodium clavatum is 20kg, pulverized, extracted with 120L 70-85% methanol under reflux for 3 times (2 hr each time at 70-85 deg.C), the extractive solution is concentrated into 2kg of total fluid extract,adding 3% tartaric acid water solution and ethyl acetate into the fluid extractThe ester was suspended to 25L and the aqueous phase was replaced with saturated Na2CO3After adjusting the pH to 10, chloroform was added thereto to extract, thereby obtaining an ethyl acetate extract and a chloroform extract.
- 8. The ethyl acetate extract of claim 4, wherein the main effective ingredients are: furfural (furfurfuraldehyde), monomethyl fumarate (monomethylfumarate), methyl dihydroferulic acid (dihydroferulic acid methyl ester), ethyl dihydroferulic acid (dihydroferulic acid ethyl ester), ethyl caffeate (caffeic acid ethyl ester), 5, 7-dihydroxy-2-methylchromone (5, 7-dihydroxy-2-methyl chloride), abscisic acid (abscisic acid), ethyl nervonate (ethyl orsellinate), 4-methoxybenzoic acid (4-methoxybenzoic acid), vanillic acid (vanillic acid).
- 9. The chloroform extract of the extract according to claim 5, which comprises the following main effective components: lycoserramine-M N-oxide, acetyl-lycoserramine-M, lycopodine (lycopodine), lycoserramine-M, miyoshinine C, 12-epoxydoline N-oxide, gnidiiodine, lycoserramine-K, lucidiline (lucidiline), 4 alpha-hydroxyyanhydroxodiol, flubelline; hydroxypyrodine, lycopodine (lycodine), des-N-methyl-alpha-phellodendrine (des-N-methyl-alpha-obstrurine), alpha-phellodendrine (alpha-obstrurine), des-N-methyl-beta-phellodendrine (des-N-methyl-beta-obstrurine), lycopodrine (lycoflexine), lycoflexidine N-oxide, fabridine (facettidine), N-oxideopine M.
- 10. Extract for use according to claims 2-9, in the form of a pharmaceutical preparation, in the form of an oral preparation selected from the group consisting of tablets, powders, oral liquids, capsules, granules and syrups.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210135820.6A CN114392260A (en) | 2022-02-15 | 2022-02-15 | Medicine for relieving anxiety and depression |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210135820.6A CN114392260A (en) | 2022-02-15 | 2022-02-15 | Medicine for relieving anxiety and depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114392260A true CN114392260A (en) | 2022-04-26 |
Family
ID=81234867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210135820.6A Pending CN114392260A (en) | 2022-02-15 | 2022-02-15 | Medicine for relieving anxiety and depression |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114392260A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103372174A (en) * | 2012-04-27 | 2013-10-30 | 王宇红 | Compound traditional Chinese medicine for treating depression |
| CN103980198A (en) * | 2013-02-08 | 2014-08-13 | 复旦大学 | Alkaloid Casuarinine H and use thereof in preparation of medicines for treating neurodegenerative diseases |
| CN104490972A (en) * | 2015-01-06 | 2015-04-08 | 山西大学 | Pharmaceutical composition for treating and preventing depression and preparation method of pharmaceutical composition |
| CN104771451A (en) * | 2015-04-24 | 2015-07-15 | 中国人民解放军第二军医大学 | Traditional Chinese medicine extract with antidepressant effect and application thereof |
| CN105943618A (en) * | 2016-06-14 | 2016-09-21 | 云南瑞酚生物科技有限公司 | Drug for treating depression |
| CN110251543A (en) * | 2019-07-29 | 2019-09-20 | 珠海俊一健生物医药科技有限公司 | Become application of the leaf tree conopsea extraction in preparation antidepression natural drug |
-
2022
- 2022-02-15 CN CN202210135820.6A patent/CN114392260A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103372174A (en) * | 2012-04-27 | 2013-10-30 | 王宇红 | Compound traditional Chinese medicine for treating depression |
| CN103980198A (en) * | 2013-02-08 | 2014-08-13 | 复旦大学 | Alkaloid Casuarinine H and use thereof in preparation of medicines for treating neurodegenerative diseases |
| CN104490972A (en) * | 2015-01-06 | 2015-04-08 | 山西大学 | Pharmaceutical composition for treating and preventing depression and preparation method of pharmaceutical composition |
| CN104771451A (en) * | 2015-04-24 | 2015-07-15 | 中国人民解放军第二军医大学 | Traditional Chinese medicine extract with antidepressant effect and application thereof |
| CN105943618A (en) * | 2016-06-14 | 2016-09-21 | 云南瑞酚生物科技有限公司 | Drug for treating depression |
| CN110251543A (en) * | 2019-07-29 | 2019-09-20 | 珠海俊一健生物医药科技有限公司 | Become application of the leaf tree conopsea extraction in preparation antidepression natural drug |
Non-Patent Citations (2)
| Title |
|---|
| DONGKE MA，ET AL: ""Pharmacokinetic Studies of Three Alkaloids in Rats After Intragastrical Administration of Lycopodii Herba Extract by LC-MS/MS"", 《MOLECULES》, vol. 24, pages 297 - 12 * |
| 张东博: ""四种药用植物中生物碱类化学成分的结构及生物活性研究"", 《中国优秀硕士学位论文数据库医药卫生科技辑》, pages 076 - 099 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101181317B (en) | Purslane extract as well as preparation method and application thereof | |
| CN1977951B (en) | Gastrodia elata plant extract for preventing senile dementia and its preparing method | |
| CN102133384A (en) | Ginger and dried orange peel composition, preparation method thereof and application of ginger and dried orange peel composition in preparation of attenuated synergistic medicaments in cancer radiotherapy and chemotherapy | |
| CN104435226B (en) | Fevervine extract and application thereof | |
| CN104825461A (en) | Neuro-protection application of ganoderma leucocontextum extract | |
| CN102091314B (en) | Composition of dried ginger and evodia rutaecarpa, preparation method thereof and application thereof in preparing attenuating synergistic medicament in radiotherapy and chemotherapy of cancer | |
| CN103263490A (en) | Extract from traditional Chinese medicine and its preparation method | |
| CN107837301B (en) | Piper laetispicum extract and preparation method and application thereof | |
| CN1840162A (en) | Compound total extract of compound cape jasmine, ginger and fermented soybean, its preparation and use | |
| CN102178721B (en) | Application of fiveleaf gynostemma herb suspension and extract to preparation of drug for treating and resisting depression | |
| CN109806304A (en) | The preparation method of three leaf raspberry plant extracts and its pharmaceutical composition and anti-trichina purposes | |
| CN114392260A (en) | Medicine for relieving anxiety and depression | |
| CN108785370A (en) | A kind of pharmaceutical composition for treating hyperlipemia and atherosclerosis | |
| CN101919924B (en) | Pharmaceutical composition for curing tristimania and preparation method and application thereof | |
| CN103340962A (en) | Natural pharmaceutical composition, and preparation method and application thereof | |
| CN102552847B (en) | Ginger and inula flower composition for reducing vomiting caused by cancer chemotherapy and increasing curative effect for chemotherapy and preparing method thereof | |
| CN104998034A (en) | Chinese herbal medicine combination drug treating livestock respiratory diseases and preparation method thereof | |
| CN109820883A (en) | Metapanax plant extracts and its pharmaceutical composition preparation method and its antiulcer purposes | |
| CN104906214B (en) | The combined preparation process of flavonoids and triterpene acid in a kind of loguat leaf | |
| CN103263492A (en) | Traditional chinese medicine extract | |
| CN104288169B (en) | A kind of flavonoid glycoside compound and its production and use | |
| CN103211898A (en) | Traditional Chinese medicine extractive and preparation method thereof | |
| CN112694441B (en) | C 20 Diterpenoid alkaloids, their preparation and use for treating pain related diseases | |
| CN103222996A (en) | Coreopsis tinctoria refined extract and medical application thereof | |
| CN102070597A (en) | Amide alkaloid and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220426 |